Payment overview · 2025
General Payments
$455.68
20 reported records · 9 companies
Healthcare provider profile · identity verified
Muneel Abbas, MD
Allopathic & Osteopathic Physicians|Family Medicine · WILLIAMSON, WV · NPI 1740404375
Verified facts
What the public records show
CMS Open Payments records show Muneel Abbas, MD received $455.68 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tresiba by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.63 | 32.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.27 | 15.0% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $64.97 | 14.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $59.85 | 13.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.44 | 8.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.63 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.60 | 4.3% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.07 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.22 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $455.68 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.52 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $106.85 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.27 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $64.97 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 883 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 877 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 726 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 530 | 122 |
| Lisinopril | Lisinopril | 497 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 488 | 46 |
| Metformin Hcl | Metformin Hcl | 477 | 92 |
| Furosemide | Furosemide | 463 | 83 |
| Omeprazole | Omeprazole | 450 | 81 |
| Clonazepam | Clonazepam | 437 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 77 |
| Potassium Chloride | Potassium Chloride | 342 | 73 |
| Carvedilol | Carvedilol | 327 | 60 |
| Famotidine | Famotidine | 325 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 313 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 68 |
| Donepezil Hcl | Donepezil Hcl | 279 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 71 |
| Glipizide | Glipizide | 267 | 53 |
| Buspirone Hcl | Buspirone Hcl | 260 | 57 |
| Tramadol Hcl | Tramadol Hcl | 245 | 38 |
| Eliquis | Apixaban | 243 | 52 |
| Lorazepam | Lorazepam | 238 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 235 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 52 |
| Ezetimibe | Ezetimibe | 224 | 61 |
| Ropinirole Hcl | Ropinirole Hcl | 221 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 45 |
| Azithromycin | Azithromycin | 217 | 133 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 91 |
| Alprazolam | Alprazolam | 204 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 200 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 73 |
| Losartan Potassium | Losartan Potassium | 195 | 46 |
| Levetiracetam | Levetiracetam | 193 | 23 |
| Pregabalin | Pregabalin | 193 | 28 |
| Simvastatin | Simvastatin | 181 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 29 |
| Montelukast Sodium | Montelukast Sodium | 170 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 18 |
| Divalproex Sodium | Divalproex Sodium | 148 | 17 |
| Trazodone Hcl | Trazodone Hcl | 143 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 136 | 63 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 25 |
| Ozempic | Semaglutide | 133 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 25 |
| Spironolactone | Spironolactone | 115 | 22 |
| Sertraline Hcl | Sertraline Hcl | 114 | 26 |
| Mirtazapine | Mirtazapine | 113 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 14 |
| Allopurinol | Allopurinol | 108 | 25 |
| Farxiga | Dapagliflozin Propanediol | 101 | 29 |
| Risperidone | Risperidone | 99 | suppressed |
| Lamotrigine | Lamotrigine | 98 | 13 |
| Methocarbamol | Methocarbamol | 94 | 34 |
| Glimepiride | Glimepiride | 93 | 13 |
| Entresto | Sacubitril/Valsartan | 92 | 14 |
| Jardiance | Empagliflozin | 92 | 28 |
| Ibuprofen | Ibuprofen | 91 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 90 | suppressed |
| Cephalexin | Cephalexin | 90 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 23 |
| Xarelto | Rivaroxaban | 87 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 19 |
| Levofloxacin | Levofloxacin | 84 | 62 |
| Nystatin | Nystatin | 84 | 28 |
| Benztropine Mesylate | Benztropine Mesylate | 83 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 83 | 22 |
| Levalbuterol Hcl | Levalbuterol Hcl | 80 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 54 |
| Memantine Hcl | Memantine Hcl | 79 | 17 |
| Fluconazole | Fluconazole | 78 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 16 |
| Januvia | Sitagliptin Phosphate | 74 | 12 |
| Methylprednisolone | Methylprednisolone | 73 | 54 |
| Diazepam | Diazepam | 72 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 69 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 22 |
| Meloxicam | Meloxicam | 68 | 26 |
| Topiramate | Topiramate | 68 | 15 |
| Ammonium Lactate | Ammonium Lactate | 67 | 20 |
| Aripiprazole | Aripiprazole | 67 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 65 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 47 |
| Ventolin Hfa | Albuterol Sulfate | 64 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 18 |
| Sucralfate | Sucralfate | 62 | 18 |
| Novolog | Insulin Aspart | 61 | 11 |
| Mounjaro | Tirzepatide | 60 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 12 |
| Atenolol | Atenolol | 58 | suppressed |
| Finasteride | Finasteride | 58 | suppressed |
| Lactulose | Lactulose | 57 | 15 |
| Ranolazine Er | Ranolazine | 57 | suppressed |
| Digoxin | Digoxin | 54 | suppressed |
| Torsemide | Torsemide | 53 | 17 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 52 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | suppressed |
| Celecoxib | Celecoxib | 51 | 16 |
| Doxepin Hcl | Doxepin Hcl | 51 | 18 |
| Meclizine Hcl | Meclizine Hcl | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 48 | 11 |
| Fenofibrate | Fenofibrate | 48 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 45 | 45 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 44 | 42 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Levemir | Insulin Detemir | 43 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 43 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Kerendia | Finerenone | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 41 | suppressed |
| Tradjenta | Linagliptin | 41 | suppressed |
| Linzess | Linaclotide | 40 | 15 |
| Multaq | Dronedarone Hcl | 40 | suppressed |
| Vascepa | Icosapent Ethyl | 40 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 16 |
| Theophylline Er | Theophylline Anhydrous | 36 | suppressed |
| Buprenorphine | Buprenorphine | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 13 |
| Amoxicillin | Amoxicillin | 34 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Insulin Aspart | Insulin Aspart | 31 | 11 |
| Lidocaine | Lidocaine | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Nitroglycerin | Nitroglycerin | 31 | 20 |
| Cilostazol | Cilostazol | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Xifaxan | Rifaximin | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Insulin Lispro | Insulin Lispro | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Butrans | Buprenorphine | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Ibu | Ibuprofen | 21 | 11 |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 17 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 12 |
| Scopolamine | Scopolamine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Perphenazine | Perphenazine | 15 | suppressed |
| Probenecid | Probenecid | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Tresiba | Insulin Degludec | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Enbrel | Etanercept | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Imiquimod | Imiquimod | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $455.68 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, EVENITY, FARXIGA, Kerendia, LINZESS, MOUNJARO, Ohtuvayre, Ozempic, REXULTI, Rybelsus | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error